Key result
Preoperative ACEI, ARB, beta-blocker, or statin use did not associate with post-CPB vasoplegia, whereas ARNI use did.
Why the study?
Postcardiotomy vasoplegia after cardiopulmonary bypass involves a blunted renin and Angiotensin II response, and many cardiac surgery patients take RAAS-modifying medications preoperatively. Whether preoperative use of RAAS-inhibiting medications is associated with CPB-associated vasoplegia required investigation.
Does preoperative use of RAAS-inhibiting medications associate with the incidence of postoperative vasoplegia in elective cardiopulmonary bypass patients?
Cohort (n=66)
No
Does preoperative use of RAAS-inhibiting medications associate with the incidence of postoperative vasoplegia in elective cardiopulmonary bypass patients?
Answers are grounded in this paper and cite their sources.
Preoperative use of ACE inhibitors, ARBs, beta-blockers, and statins did not correlate with post-cardiopulmonary bypass vasoplegia, though preoperative ARNI use showed a positive association in a very small sample.
Introduction Postcardiotomy vasoplegia affects ∼20% of cardiopulmonary bypass (CPB) patients and associates with acute kidney failure, prolonged hospital stay, and mortality. Preliminary work revealed that nonvasoplegic CPB patients exhibit an immediate and robust increase in renin and Angiotensin II (Ang II), while vasoplegic patients exhibit a blunted renin and Ang II response. As many cardiac surgery patients are receiving renin-angiotensin-aldosterone (RAAS)-modifying medications preoperatively, this cohort study investigated if preoperative use of RAAS-inhibiting medications is associated with CPB-associated vasoplegia. Methods Sixty-six elective CPB patients at our tertiary referral center were prospectively enrolled and categorized as vasoplegic or nonvasoplegic based on immediate postoperative vasopressor requirements and cardiac index. Rates of preoperative medication use between nonvasoplegic and vasoplegic patients were compared: ACE inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta-adrenergic blockers, ARB-neprilysin inhibitors (ARNI), statins and mixed polypharmacy groups were evaluated. Results Forty-nine patients were non-vasoplegic controls compared to 17 vasoplegic patients. All three patients on ARNI preoperatively became vasoplegic (3/17 (17.6%), versus 0/49 nonvasoplegic (0%), P = 0.015). For all other groups – patients on a beta blocker, ACEI, ARB, statin, or any combination of these medications – rates of pre-operative medication did not associate significantly with vasoplegia status. Conclusions The use and timing of discontinuation of pre-operative beta-adrenergic blocker, ACEI, ARB, and statin did not correlate with the incidence of post-operative vasoplegia. The use of ARNIs was positively associated with vasoplegia in a limited sample size. As a result, we believe post-CPB vasoplegia may have a separate pathway from preoperative RAAS modulators that requires further investigation.
No takes yet. Share an insight, caveat, or question.
Tingey et al. (2026) conducted a cohort in Elective cardiopulmonary bypass (CPB) (n=66). Preoperative RAAS-modifying medications (ACE inhibitors, ARBs, ARNIs) as well as beta-adrenergic blockers and statins vs. Non-vasoplegic cardiopulmonary bypass controls (n=49 vs n=17 vasoplegic) was evaluated on Rates of preoperative medication use in post-CPB vasoplegic vs nonvasoplegic patients (specifically preoperative ARNI use) (p=0.015). Preoperative ACEI, ARB, beta-blocker, or statin use did not associate with post-CPB vasoplegia, whereas ARNI use did.
Synapse has enriched 10 related papers. Consider them for comparative context: